DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in
clinical research.
Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their disease:
- has come back after remission
- is not responding to current treatment
This study has three parts:
1. Dose Escalation is to find the safe dose of DS-3201b that adults with advanced NHL can
tolerate.
2. Dose Expansion is to:
- find out how effective DS-3201b is for rare types of NHL
- collect additional safety data
3. Drug-Drug Interaction (DDI) Cohort (US Only) is to evaluate the effect of DS-3201b on
the pharmacokinetics (PK) midazolam and digoxin when co-administered to patients with
NHL